Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company developing orally administered antiviral treatments for serious viral diseases. Its pipeline includes bemnifosbuvir and ruzasvir, an investigational combination regimen for chronic hepatitis C virus (HCV) infection, and AT-587, a product candidate for chronic hepatitis E virus (HEV) infection, particularly in immunocompromised patients. The company’s proprietary nucleos(t)ide platform supports discovery and development of antiviral candidates targeting single-stranded RNA viruses. Atea is conducting Phase 3 trials of bemnifosbuvir and ruzasvir and developing AT-587 toward clinical testing. It aims to commercialize its candidates if they are successfully developed and approved. The company is headquartered in Boston, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AVIR in the last 30 days.
See all $AVIR insider activity →Atea Pharmaceuticals (AVIR) reported successful Phase III trials, with C-BEYOND meeting non-inferiority endpoints. The company aims for mid-2027 NDA submission, backed by $191.2 million in cash and a $65 million credit facility. AT-587 is advancing in Phase I trials.
Atea Pharmaceuticals (AVIR) reported positive phase 3 results for its hepatitis C treatment, BEM/RZR, meeting primary endpoints. The company secured a $200M credit facility for U.S. market entry, ending Q3 with $191.2M in cash. AVIR aims for a $2.5B U.S. market opportunity, projecting $700M in peak annual sales.
Atea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection P
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning AVIR (Atea Pharmaceuticals, Inc.). Coverage has skewed bullish: 9 bullish, 2 neutral, and 0 bearish.
Recent AVIR coverage spans financial news, earnings and corporate actions.
Positive trial data and strong cash position likely boost investor sentiment.
Positive trial data is likely to drive the stock higher as investors price in potential market launch.
Positive pivotal trial data likely lifts AVIR valuation as the regimen shows non‑inferiority to an approved therapy.
The new financing provides significant capital for development and commercialization of the company's lead drug, likely supporting the stock.
The financing provides significant capital for clinical development but adds debt and covenants, likely pressuring the stock.
AlphAI scores every news story that mentions AVIR with an AI model for sentiment and relevance, and aggregates insider trades from Atea Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Atea Pharmaceuticals (AVIR) reported successful Phase III trials, with C-BEYOND meeting non-inferiority endpoints. The company aims for mid-2027 NDA submission, backed by $191.2 million in cash and a $65 million credit facility. AT-587 is advancing in Phase I trials.
Atea Pharmaceuticals (AVIR) reported positive phase 3 results for its hepatitis C treatment, BEM/RZR, meeting primary endpoints. The company secured a $200M credit facility for U.S. market entry, ending Q3 with $191.2M in cash. AVIR aims for a $2.5B U.S. market opportunity, projecting $700M in peak annual sales.
Atea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Achieved Primary and Secondary Endpoints, Reinforcing Potential Best-in-Class Profile of BEM/RZR for Treatment of Hepatitis C Virus (HCV) Infection P
Atea Pharmaceuticals (AVIR) secured a $200 million loan facility from Hercules Capital, with $65 million funded initially. The loan, maturing in 2031, supports BEM/RZR development and commercialization, with interest-only payments for 48 months.
Atea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 6, 2026 (the “Closing Date”), Atea Pharmaceuticals, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Agreement”) with Hercules Capital, Inc. (“Hercules”), as agent, and the lenders party theret
Atea Pharmaceuticals (AVIR) reported Q2 2026 earnings, highlighting $219.5M in cash and marketable securities, a net loss of $32.9M, and a 93.9% SVR rate for its lead regimen BEM/RZR. Management projected a cash runway through 2027 and a commercial launch in mid-2028. The company also initiated Phase 1 trials for AT-587, targeting chronic hepatitis E.
Atea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Phase 3 C-BEYOND Trial Met Primary and Secondary Endpoints, with a Short 8-week Duration for Patients Without Cirrhosis Supporting a Potential Best-in-Class Profile of BEM
Atea Pharmaceuticals (Nasdaq: AVIR) said it started a first-in-human Phase 1 trial of AT-587, an oral nucleotide analog for hepatitis E virus (HEV), in healthy volunteers. The randomized, double-blind, placebo-controlled study will assess safety, tolerability and PK, with single and multiple ascending doses plus a food-effect arm. Preclinical data cited include 30-150x in vitro potency vs sofosbuvir/ribavirin and in vivo genotype 3 activity.
Atea Pharmaceuticals, Inc. (AVIR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001593899 0001593899 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18,
Atea Pharmaceuticals director Polly A. Murphy purchased 6,100 shares of Common Stock on the open market at a weighted average price of $4.1715 per share on May 18, 2026. This transaction increased her direct ownership to 92,145 shares. The filing, an amended Form 4/A, corrected the transaction date from May 18, 2025, to May 18, 2026.
